Alvogen Expands Development and Commercialization Collaboration with Pfenex for PF708 in EU, MENA and ROW

 Alvogen Expands Development and Commercialization Collaboration with Pfenex for PF708 in EU, MENA and ROW

Alvogen Expands Development and Commercialization Collaboration with Pfenex for PF708 in EU, MENA and ROW

Shots:

  • Pfenex to receive $2.5M as upfront and milestones for EU & MENA, milestones for ROW & 60% profit split on sales. Alvogen’s subsidiary Theramex & SAJA to get rights to develop and commercialize in EU, Switzerland & MENA respectively (Ex-Mainland China, Hong Kong, Singapore, Malaysia and Thailand) undisclosed in ROW
  • On 11 Jun,2018 Pfenex & Alvogen collaborated for the development and commercialization of Pfenex’s PF708 in the US
  • Pfenex’s PF708 (teriparatide, biosimilar) is evaluated in P-III study for patients with osteoporosis and is expected to be approved by the US FDA in Q4’19

Click here to read full press release/ article | Ref: Pfenex | Image: Twitter

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post